Treatment of Atrial Fibrillation and Flutter: Focus on Oral Dofetilide, a New Selective Class III Antiarrhythmic Agent

Publisher： Karger

E-ISSN： 1424-0556|1|6|320-331

ISSN： 1422-9528

Source： Heart Drug, Vol.1, Iss.6, 2002-02, pp. : 320-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation

By Torp-Pedersen C.   Brendorp B.   Køber L.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2695-2704

Informa Healthcare

Access to resources Recommend Favorite

New antiarrhythmic agents for atrial fibrillation and atrial flutter

By Pecini Redi   Elming Hanne   Pedersen Ole Dyg   Torp-Pedersen Christian  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 2, 2005-05 ,pp. : 311-322

Informa Healthcare

Access to resources Recommend Favorite

Dofetilide: A Review of its Use in Atrial Fibrillation and Atrial Flutter

By McClellan K.J.   Markham A.  

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 1043-1059

Adis International

Access to resources Recommend Favorite

Azimilide dihydrochloride: a new class III anti-arrhythmic agent

By Abrol R.   Page R.L.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2705-2715

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological Treatment of Atrial Fibrillation: Mechanisms of Action and Efficacy of Class III Drugs

By  

Current Medicinal Chemistry, Vol. 13, Iss. 14, 2006-06 ,pp. : 1635-1653

Bentham Science Publishers

Access to resources Recommend Favorite